Health Information Services. Scored on the same transparent model behind the daily rankings.
★
PRVA
Privia Health Group, Inc. · Health Information Services
56.0Score
$20.85Oct 9 close$2.7B
1Y Target$31.47Analyst consensus · 17 analysts
5Y Target$46.08Compound horizon
10Y Target$68.35Long-dated conviction
FCF$131mTTM · 06/26C
FCF $131m — modest; watch for margin expansion · TTM from SEC filings (OCF − CapEx), four quarters to 06/26.
Rev+24.1%TTM YoYA-
Revenue +24.1% — strong growth, well above S&P median (~7%) · Latest four quarters of revenue vs the four before them, from SEC filings.
D/E0.01A-
D/E 0.01 — less debt than most Healthcare peers (≈25th pctile)
P/E99.3xD
P/E 99.3 — most expensive decile in Healthcare (≈95th pctile)
PEG27.41est.D
PEG 27.41 — very expensive; pricing in best-case scenarios · PEG derived: P/E ÷ analysts' expected EPS growth for next year, because this name has no vendor-supplied PEG. When earnings are expected to dip this year, the growth used is the yearly average over this year and next, so a recovery isn't counted as growth.
Targets: 1-year is analyst consensus where covered, 5- and 10-year are model estimates; the DCF is a cross-check, not a target. Methodology
Quality-growth score · 56
Quality44.2
Growth78.7
Value50.4
Why this score
Diluting shareholders
Entry · Margin of safety
52-week rangeNear 52-week low
28% off the 12-month high
vs DCF fair value20% belowest. fair value ~$26
What the price assumes: free cash flow growing about 7% next year, slowing to 4% a year by year ten — vs a starting rate of ~21% our model takes as the middle of three readings — analyst estimates, last year's revenue growth, and the company's own multi-year record.
Quality signals
ROIC4.5% · C+return on invested capital — leads the quality score
Model-generatedFrom reported fundamentals, checked against the figures above · Editorial standards
Why now
Health Information Services · market cap $2.7b. Down 28% from 52-week high of $28.82 — deep drawdown territory. Revenue growing +24%, comfortably above the S&P median. 17 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $31.47 (implying +51% upside).
Moat
Free cash flow runs well ahead of reported net income, mostly because of stock-based pay ($76m) — a real cost to shareholders, paid in shares rather than cash.
Risk
Trailing P/E 99.3x prices in sustained high growth — any quarter that disappoints triggers sharp re-rating. Net margin 1.2% is thin — operating leverage cuts both ways; input-cost inflation or pricing pressure hits the bottom line first. ROE 4% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate.
Horizon
1-3 yr $31.47 (17-analyst consensus) — fundamentals + valuation re-rating. 5 yr $46.08 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $68.35 if current growth sustains into durable earnings power.
PRVA vs the Top Picks average
Pillar
PRVA
Book avg
Diff
Quality
44
83
-39
Growth
79
89
-10
Value
50
76
-26
Average of today's Top 30 (mean score 82.6); size and sector limits also decide the book.
Score history · PRVA
Trend
+9.8 over 82 daily scores
From 46.2 (Jun 22) → 56.0 (now)
One point per daily run; read From → To for the actual range.
PRVA at a glance
Same audited fundamentals as the score, unless a card says otherwise.
Analyst estimate revisions
30-day change
-0.0%
90-day change
-3.2%
Forward EPS estimate
$1.06
Over the last 90 days, what analysts expect PRVA to earn is drifting lower (-3.2%). The estimate is derived from price and forward P/E captured at the same instant, so a moving share price does not move this number — only a changed forecast does.
Estimates move both ways and are not part of the Bull Rankings score. Biggest movers →
Position sizing · PRVA
$
%
%
Shares to buy
95
Position size
$1,981
4.0% of portfolio
Stop price
$15.64
25% below $20.85
$ at risk if stopped
$495.19
budget $500.00 · 1% of portfolio
Math only: excludes commissions, slippage and gap risk. Inputs stay in your browser.
Privia Health Group, Inc. (PRVA): score, valuation & FAQ
Privia Health Group, Inc. (PRVA) is a Health Information Services company that scores 56 out of 100 on the Bull Rankings quality-growth model — a middling reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are Rev (A-) and D/E (A-), while P/E (D) and PEG (D) rate weaker. On valuation, PRVA sits about 20% below our discounted-cash-flow fair value (a margin of safety) — the current price implies free cash flow growing about 7% next year, slowing to 4% a year by year ten.
Is PRVA a good stock to buy?
Bull Rankings scores PRVA 56 out of 100 on its quality-growth model, which is a middling reading. That is driven by Rev (A-) and D/E (A-). A score is a quantitative screen of Privia Health Group, Inc.'s fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does PRVA score 56 on Bull Rankings?
The score leans on growth at 78.7 out of 100, with quality the weakest pillar at 44.2 — the three combine geometrically, so a weak one cannot be papered over by a strong one. PRVA earns its highest marks on Rev (A-) and D/E (A-), and is held back by P/E (D) and PEG (D). Each signal is graded against sector-aware thresholds rather than one absolute bar, so PRVA is measured against Health Information Services peers, not against the market as a whole.
Is PRVA overvalued or undervalued?
Based on $20.85, PRVA sits about 20% below our discounted-cash-flow fair value (a margin of safety) — the current price implies free cash flow growing about 7% next year, slowing to 4% a year by year ten. It trades at a 99.3x P/E (graded D). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in PRVA?
Trailing P/E 99.3x prices in sustained high growth — any quarter that disappoints triggers sharp re-rating. Net margin 1.2% is thin — operating leverage cuts both ways; input-cost inflation or pricing pressure hits the bottom line first. ROE 4% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate.